Discover Pharmagene

Updated: Sep 24
Behind every great scientific organisation are the people driving its vision, innovation and commitment to scientific excellence. In this leadership interview, Dr Amanda Woodrooffe, Chief Scientific Officer, and Richard Willock, Chief Business Officer, share their perspectives on Pharmagene® Discovery Services, its heritage in human tissue-based research and the opportunities ahead.
Pharmagene® has a long-established history in human tissue research, built on decades of experience delivering customised studies for pharmaceutical and biotechnology companies around the world. Since its origins in 1996, the organisation has worked across a broad spectrum of human diseases, applying evolving technologies and scientific approaches to help address complex questions throughout drug discovery and development.
This experience has helped shape the breadth of capabilities offered today, spanning disease characterisation, target and biomarker discovery and validation, cellular biology, bioassays, spatial biology, biotherapeutic safety and clinical sample support. Underpinning these services is an experienced scientific team with extensive knowledge of human tissue and disease biology, together with a track record of developing tailored assays and adopting new technologies in response to changing research needs.
Now operating as an independently managed UK company, Pharmagene® is building on this established scientific foundation while creating greater agility to invest in new capabilities, respond to emerging areas of research and develop new opportunities for its clients.
From the growing role of human tissue-based models and spatial biology to the emergence of AI-enabled drug discovery, Amanda and Richard discuss how Pharmagene® is combining its heritage with new technologies, scientific approaches and commercial opportunities to support the next generation of discovery and translational research.

Dr Amanda Woodrooffe, Chief Scientific Officer
Amanda is an experienced leader of scientific operations, with 30 years’ experience in drug discovery, preclinical and clinical research in the biopharma (GSK companies, Pharmagene®) and CRO industries (Pharmagene®, Asterand Bioscience, BioIVT, Precision for Medicine). She has been responsible for the current UK laboratory services business for over 15 years. Prior to this, she held various positions at the organisation, responsible for scientific strategy, business partnerships, pharmaceutical licensing, and supporting corporate development. Amanda received her PhD from the University of Cambridge.

Which aspects of Pharmagene®’s scientific capabilities are you most proud of?
I’m most proud of our team - their scientific expertise, enthusiasm, adaptability, ability to push boundaries, and all the things we have achieved together during the last 30 years.
In addition to scoping and delivering hundreds of tailored client research projects, no two of which are the same, we have developed numerous platforms and novel assays that enable us to generate the most relevant and meaningful data to progress, or decide not to progress, research programmes.
Our reputation for doing a great job for our clients, delivering the best scientific solutions and data is underpinned by the team’s focus, dedication and ability to build lasting relationships with our research partners. Our clients come back repeatedly because they like working with the team!
I am proud to see repeated success from our investments in R&D to create human tissue-based solutions that have demonstrated real scientific impact and commercial traction.
With all of this, we really have quite a unique set of scientific capabilities combining the team’s expertise and way of working across all our assay platforms.
I’m also very proud that we have played an integral part of the enabling, early adoption and growth of the human tissue-based research sector. Nowadays it is integrated into every preclinical and discovery programme and that is exactly what our original founders back in 1996 sought to achieve - I believe we are still making them proud!
Where do you see the biggest scientific opportunities in human tissue–based discovery over the next few years, and how is Pharmagene® integrating emerging technologies, such as spatial biology, into its services?
I’m delighted that human tissue-based data are now being generated routinely in support of disease characterisation, target and biomarker discovery and validation and beyond.
Firstly, I’ll start with a more practical, but perpetually challenging, opportunity for the industry. The ability to source high-quality human tissues for discovery research is not always easy, especially in rare disease or very specific disease subtypes. As we implement cutting-edge technologies which allow us to learn more about individual diseases and continue to seek personalised treatments, I think that a critical opportunity for the established human biospecimen providers is to find ways to better access tissues from niche disease indications that are fully consented for commercial pharmaceutical research. These samples support not only discovery research in these patient populations but are essential for the development and validation of bioassays that will be used throughout clinical and diagnostic development.
There has been a strong focus on alternatives to replacement of animals in preclinical research for many years, with the UK often leading the way through our National Centre for the 3Rs (NC3Rs). With the FDA announcing in April 2025 its plans to phase out animal testing requirements for novel biotherapeutics and other drug modalities, and the UK government issuing a policy paper in November 2025 presenting their strategic plan to support the development, validation and uptake of alternative methods, this renewed focus presents a huge opportunity for human tissue-based discovery over the coming years. As a specialist CRO focused on development of human tissue and cell-based assays, Pharmagene® is well placed to apply our knowledge and expertise to support this ongoing effort to create robust in vitro assays that can not only help to replace animal testing but add value with relevant human biological data.
With the rapid emergence of increasingly high content and spatial biology platforms, and tools to enable the study of protein-protein interactions in tissues, researchers are now able to take a much deeper dive into disease biology to uncover novel mechanisms, targets, protein interactions and spatial cellular relationships in diseased tissue microenvironments. Over recent years we have successfully integrated such platforms to enable us to understand and exploit the role of the immune system in targeting disease including autoimmune, oncology and fibrosis. We now routinely support a plethora of different projects using tailored multiplex immunofluorescence IHC (mIF), RNAscope™ ISH and in situ Proximity Ligation Assay (isPLA) and we continue to evaluate higher-plex spatial platforms that will have specific application and impact for our research clients. We have a strong track record of implementing new platforms, so watch this space!
RNAscope™ is a trademark of Bio-Techne.
What excites you most about the science your teams are enabling right now?
Our team have a great track record of developing novel approaches and assays to provide relevant data to support a range of research programmes.
Often, we are tasked with complex biological and scientific questions. One exciting area for us is the ongoing emergence of novel biotherapeutic modalities and the associated scientific challenges of working out how to design and develop relevant assays for these. In addition, with the rapid emergence of AI-enabled discovery based on interrogation of big datasets, I think one of the most exciting applications for our skill set and scientific approach is the design and execution of experimental approaches to evaluate and validate novel hypotheses arising from AI-enabled discovery.
High quality, robustly generated, human data are essential for helping to develop novel AI-based approaches and models. One particular platform Pharmagene® offers to support this is our extensive collection of XpressWay™ Profiles, a unique dataset of whole-body target expression profiles generated using validated quantitative reverse transcription polymerase chain reaction (RT-qPCR) methodologies. These high-quality human tissue expression data provide a valuable resource for both AI-driven discovery organisations and those deploying more traditional approaches.
Finally, seeking ways to unlock the biological data from the thousands of individual samples in our internal research biobank will further enable ongoing AI-based approaches for drug discovery, development and diagnostics across a broad range of disease indications. There is a lot to be excited about!
Richard Willock, Chief Business Officer
Richard has over 25 years’ experience in the life sciences industry having worked as a research scientist for GSK and PerkinElmer, and a decade working for this company under previous ownership (Asterand PLC). He has spent the last 15 years working in commercial roles, including 7 years as CBO and Board member of DefiniGEN Ltd. He brings a solid track record of commercial success to the company, having built trusted business relationships with companies across the USA and Europe.

What can clients expect in terms of engagement, communication and project management when working with Pharmagene®?
We have built a loyal client base over many years, something we are very proud of. Clients can continue to expect the scientific rigour, responsive communication and timely delivery that have long been central to the way we work.
We pride ourselves on a collaborative, consultative approach, supported by an experienced team that understands both the scientific challenges our clients face and the importance of building strong, long-term research partnerships.
Where do you see the greatest opportunities to expand Pharmagene®’s services, geographic reach and strategic partnerships?
Pharmagene® have always been pioneers in using human samples to support drug discovery, and we look forward to being able to showcase our expertise to the wider international marketplace and explore new markets like AI model hypothesis testing and veterinary medicine.
The United States remains a key strategic market, offering significant potential to expand our customer base. To support this growth, we plan to strengthen our presence through regular trips to both the East and West Coasts. We also intend to actively explore new opportunities in Japan, where we see strong potential for international expansion. Alongside building new relationships, we remain committed to nurturing our existing partnerships, which are central to our success.
We have a unique angle in offering GLP Tissue Cross-Reactivity (GLP TCR) services which I’m excited to take to market – our expertise in establishing IHC protocols for biotherapeutic candidates is second to none, and companies increasingly need an agile competent partner to support this critical stage of drug development.
Looking ahead, what are you most excited about for Pharmagene® and its clients over the next few years?
Having formerly been part of a larger US-led organisation, I am excited for us to chart our own course as a UK managed autonomous company. We will invest enthusiastically in expansion of our human tissue and cell-based services to complement our clients growing requirements, all the time ensuring that scientific excellence and open consultative dialogue remain our core values.
AI is upending almost every industry, and drug development is no exception; the technology is currently generating a wealth of putative targets and therapeutic hypotheses, but these will need thorough validation to build confidence in any approach. Pharmagene® is uniquely placed to offer established expertise in preclinical target validation, so this is a timely opportunity to support this new wave of innovation.
Deriving high-quality actionable data from human biospecimens is a very specialised area but has enormous value to de-risk drug discovery, and I’m confident we can remain at the forefront of innovation in this area.
Ready to explore how our expertise in human tissue–based discovery can support your next breakthrough? Contact us to start the conversation and see how Pharmagene® can help advance your research.

